Metformin as a potential disease-modifying drug in osteoarthritis: a systematic review of pre-clinical and human studies

Abstract

Objective: Osteoarthritis causes significant pain and disability with no approved disease-modifying drugs. We systematically reviewed the evidence from both pre-clinical and human studies for the potential disease-modifying effect of metformin in osteoarthritis.

Methods: Ovid Medline, Embase and CINAHL were searched between inception and June 2021 using MeSH terms and key words to identify studies examining the association between metformin use and outcome measures related to osteoarthritis. Two reviewers performed the risk of bias assessment and 3 reviewers extracted data independently. Qualitative evidence synthesis was performed. This systematic review is registered on PROSPERO (CRD42021261052 and CRD42021261060).

Results: Fifteen (10 pre-clinical and 5 human) studies were included. Most studies (10 pre-clinical and 3 human) assessed the effect of metformin using knee osteoarthritis models. In pre-clinical studies, metformin was assessed for the effect on structural outcomes (n = 10); immunomodulation (n = 5); pain (n = 4); and molecular pathways of its effect in osteoarthritis (n = 7). For human studies, metformin was evaluated for the effect on structural progression (n = 3); pain (n = 1); and immunomodulation (n = 1). Overall, pre-clinical studies consistently showed metformin having a chondroprotective, immunomodulatory and analgesic effect in osteoarthritis, predominantly mediated by adenosine monophosphate-activated protein kinase activation. Evidence from human studies, although limited, was consistent with findings in pre-clinical studies.

Conclusion: We found consistent evidence across pre-clinical and human studies to support a favourable effect of metformin on chondroprotection, immunomodulation and pain reduction in knee osteoarthritis. Further high-quality clinical trials are needed to confirm these findings as metformin could be a novel therapeutic drug for the treatment of osteoarthritis.

Keywords: Disease-modifying; Human; Metformin; Osteoarthritis; Pre-clinical; Systematic review.

Conflict of interest statement

Conflict of interest CBL receives research funding from pharmaceutical companies (Fidia Farmaceutici, Cynata Therapeutics, Ceva Animal Health Pty Ltd and Regeneus Pty Ltd) to investigate efficacy of novel osteoarthritis therapeutics in pre-clinical models, through specific services/testing-contract research agreements between and managed by The University of Sydney or the Northern Sydney Local Health District. The other authors declare that they have no conflict of interest.

Copyright © 2022 Osteoarthritis Research Society International. Published by Elsevier Ltd. All rights reserved.